×
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
NASDAQ:ALIM

Alimera Sciences Stock Forecast, Price & News

$5.25
-0.25 (-4.55%)
(As of 06/24/2022 04:00 PM ET)
Add
Compare
Today's Range
$5.21
$5.57
50-Day Range
$4.00
$6.15
52-Week Range
$3.94
$9.79
Volume
8,169 shs
Average Volume
31,903 shs
Market Capitalization
$36.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.50
30 days | 90 days | 365 days | Advanced Chart

Receive ALIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alimera Sciences and its competitors with MarketBeat's FREE daily newsletter.

ALIM Stock Forecast (MarketRank)

Overall MarketRank

2.01 out of 5 stars

Medical Sector

582nd out of 1,418 stocks

Pharmaceutical Preparations Industry

263rd out of 679 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
Alimera Sciences logo

About Alimera Sciences (NASDAQ:ALIM)

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

ALIM Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALIM
Employees
145
Year Founded
2003

Company Calendar

Last Earnings
5/09/2022
Today
6/24/2022
Next Earnings (Estimated)
8/12/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$9.50
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+81.0%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
2 Analysts

Profitability

Net Income
$-4.37 million
Pretax Margin
-10.45%

Debt

Sales & Book Value

Annual Sales
$59.03 million
Book Value
($3.15) per share

Miscellaneous

Free Float
6,100,000
Market Cap
$36.77 million
Optionable
Optionable
Beta
1.48

Social Links















Alimera Sciences Frequently Asked Questions

Should I buy or sell Alimera Sciences stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Alimera Sciences stock.
View analyst ratings for Alimera Sciences
or view top-rated stocks.

What is Alimera Sciences' stock price forecast for 2022?

2 brokerages have issued twelve-month target prices for Alimera Sciences' shares. Their ALIM stock forecasts range from $8.00 to $11.00. On average, they anticipate Alimera Sciences' share price to reach $9.50 in the next year. This suggests a possible upside of 81.0% from the stock's current price.
View analysts' price targets for Alimera Sciences
or view top-rated stocks among Wall Street analysts.

How has Alimera Sciences' stock performed in 2022?

Alimera Sciences' stock was trading at $5.13 on January 1st, 2022. Since then, ALIM shares have increased by 2.3% and is now trading at $5.25.
View the best growth stocks for 2022 here
.

When is Alimera Sciences' next earnings date?

Alimera Sciences is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022.
View our earnings forecast for Alimera Sciences
.

How were Alimera Sciences' earnings last quarter?

Alimera Sciences, Inc. (NASDAQ:ALIM) posted its quarterly earnings data on Monday, May, 9th. The biopharmaceutical company reported ($0.85) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by $0.18. The biopharmaceutical company had revenue of $11.90 million for the quarter, compared to analysts' expectations of $13 million. During the same quarter in the previous year, the firm earned ($0.63) EPS.
View Alimera Sciences' earnings history
.

When did Alimera Sciences' stock split? How did Alimera Sciences' stock split work?

Alimera Sciences's stock reverse split before market open on Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 14th 2019. An investor that had 100 shares of Alimera Sciences stock prior to the reverse split would have 7 shares after the split.

Who are Alimera Sciences' key executives?

Alimera Sciences' management team includes the following people:
  • Mr. Charles Daniel Myers, Non-Exec. Chairman & Consultant (Age 68, Pay $205k)
  • Mr. Richard S. Eiswirth Jr., Pres, CEO & Director (Age 54, Pay $633.87k) (LinkedIn Profile)
  • Mr. David R. Holland, Co-Founder, Chief Marketing Officer and Sr. VP of Corp. Communications & Managed Markets (Age 58, Pay $448.5k)
  • Dr. Philip Ashman Ph.D., COO & Sr. VP of Commercial Operations - Europe (Age 57, Pay $462.6k)
  • Mr. John Philip Jones, Chief Financial Officer (Age 58) (LinkedIn Profile)
  • Christopher S. Visick, VP, Gen. Counsel & Sec.
  • Dr. David Dyer M.D., Chief Retina Specialist

What is Rick Eiswirth's approval rating as Alimera Sciences' CEO?

2 employees have rated Alimera Sciences CEO Rick Eiswirth on Glassdoor.com. Rick Eiswirth has an approval rating of 100% among Alimera Sciences' employees. This puts Rick Eiswirth in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alimera Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include EyePoint Pharmaceuticals (EYPT), OPKO Health (OPK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN), AngloGold Ashanti (AU), SSR Mining (SSRM), ADMA Biologics (ADMA) and Cellectar Biosciences (CLRB).

What is Alimera Sciences' stock symbol?

Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."

Who are Alimera Sciences' major shareholders?

Alimera Sciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Healthcare of Ontario Pension Plan Trust Fund (3.58%), Renaissance Technologies LLC (1.78%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own Alimera Sciences stock include James R Largent, John Philip Jones, John Snisarenko, Philip Ashman, Richard S Eiswirth Jr and Stanley Morgan.
View institutional ownership trends for Alimera Sciences
.

Which major investors are selling Alimera Sciences stock?

ALIM stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have sold Alimera Sciences company stock in the last two years include Philip Ashman, and Stanley Morgan.
View insider buying and selling activity for Alimera Sciences
or view top insider-selling stocks.

Which major investors are buying Alimera Sciences stock?

ALIM stock was acquired by a variety of institutional investors in the last quarter, including Healthcare of Ontario Pension Plan Trust Fund. Company insiders that have bought Alimera Sciences stock in the last two years include James R Largent, John Philip Jones, and Richard S Eiswirth Jr.
View insider buying and selling activity for Alimera Sciences
or or view top insider-buying stocks.

How do I buy shares of Alimera Sciences?

Shares of ALIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alimera Sciences' stock price today?

One share of ALIM stock can currently be purchased for approximately $5.25.

How much money does Alimera Sciences make?

Alimera Sciences (NASDAQ:ALIM) has a market capitalization of $36.77 million and generates $59.03 million in revenue each year. The biopharmaceutical company earns $-4.37 million in net income (profit) each year or ($1.01) on an earnings per share basis.

How many employees does Alimera Sciences have?

Alimera Sciences employs 145 workers across the globe.

When was Alimera Sciences founded?

Alimera Sciences was founded in 2003.

How can I contact Alimera Sciences?

Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The official website for Alimera Sciences is www.alimerasciences.com. The biopharmaceutical company can be reached via phone at (678) 990-5740, via email at [email protected], or via fax at 678-990-5744.

This page (NASDAQ:ALIM) was last updated on 6/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.